The SQSTM1 antibody targets the SQSTM1 protein, also known as p62. encoded by the SQSTM1 gene. This multifunctional protein serves as a critical adaptor in selective autophagy, linking ubiquitinated cargo (e.g., damaged proteins, pathogens) to autophagosomes via its ubiquitin-binding domain (UBD) and LC3-interacting region (LIR). It also regulates cellular stress responses, including the Keap1-Nrf2 antioxidant pathway, and modulates signaling cascades such as NF-κB and mTOR. Dysregulation of SQSTM1/p62 is implicated in neurodegenerative diseases (e.g., Alzheimer’s, ALS), cancer, and Paget’s disease of bone, where mutations or altered expression disrupt autophagy or signaling. In research, SQSTM1 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess protein levels, autophagic flux, or disease-associated aggregates. Elevated p62 often indicates autophagy inhibition, while its depletion may reflect enhanced degradation. These antibodies also help study tumor progression, as p62 overexpression in cancers correlates with metastasis and therapy resistance. Validating SQSTM1 antibody specificity is crucial, as splice variants and post-translational modifications (e.g., phosphorylation) can influence detection. Overall, SQSTM1 antibodies are indispensable tools for exploring autophagy, proteostasis, and disease mechanisms.